Genomic Valley Biotech faces a change in control as acquirers Pankaj Grover and Abhisek Gupta initiate an open offer for 26% of equity. Following a share purchase agreement with existing promoter Yogesh Agrawal, the new promoters are offering ₹30 per share to public shareholders. The process is scheduled to run from December 14, 2026, to December 28, 2026.
Genomic Valley Biotech: Promoters Exit as New Management Takes Over
Offer Price: ₹30 per share for 26% stake.
Total Offer Consideration: ₹2.38 crore.
Reader Takeaway: New promoters aim to revive business performance following this change in control at Genomic Valley Biotech.
What just happened
Genomic Valley Biotech (GVBL) is undergoing a significant transition as promoters Yogesh Agrawal have agreed to sell a 46.06% stake to Pankaj Grover and Abhisek Gupta at ₹30 per share. This Share Purchase Agreement, signed on October 19, 2026, has triggered a mandatory open offer for an additional 26% of the company's voting share capital. The acquirers are now set to replace the existing promoter group and take charge of the company's management.
Why this matters
This deal marks a complete shift in leadership for the biotech firm. The acquirers, who bring experience in metal components manufacturing and loan consultancy, have signaled their intent to improve the company's financial standing. For public shareholders, this provides an exit opportunity at the specified offer price of ₹30 per share.
The backstory
GVBL has seen minimal financial activity recently, reporting total income of ₹3.80 lakh and a net loss of ₹0.51 lakh for the half-year ending September 30, 2026. The incoming promoters intend to strengthen the company’s core competence and have committed to retaining significant assets for at least two years post-acquisition.
Risks to watch
Investors should note that the company has a very low revenue base, making its future performance highly dependent on the strategic changes proposed by the new owners. Tax implications on capital gains from tendering shares should be reviewed with professional advisors prior to the process.
What to track next
The tendering period for public shareholders opens on December 14, 2026, and closes on December 28, 2026. Payment for successfully tendered shares is expected to be completed by January 11, 2027. Shareholders should watch for the dispatch of the formal Letter of Offer.